A Digital Publication for the Practicing Medical Specialist, Industry Executive & Investor

No Carolina / New York

FDA IDE Approval to Initiate a Pivotal Study of the NEXUS Aortic Arch Stent Graft System Has Been Announced

Today Endospan announced they have received FDA IDE approval to initiate a pivotal study of the NEXUS Aortic Arch Stent Graft System.

NEXUS™ Aortic Arch Stent Graft System: Earlier this year, FDA granted NEXUS™ as a breakthrough device. This designation acknowledges the NEXUSTM may provide a more effective treatment for life-threatening or irreversibly debilitating diseases or conditions.

Minimally invasive techniques are standard-of-care for treating descending aortic disease and heart disease, but highly invasive, high-mortality open surgery is still being used in the difficult-to-treat aortic arch anatomy. The NEXUSTM is uniquely engineered to address this significant area of unmet clinical need. More than 120,000 patients suffer thoracic aortic arch disease every year in the USA and Europe, with only about 25% being diagnosed or treated. This global market opportunity is over $1.3 billion in a high average selling segment with no other off-the-shelf competition to the NEXUS™ technology.

The prospective and multi-arm pivotal IDE TRIOMPHE study will evaluate in up to 30 centers, the safety and effectiveness of the NEXUS™ for the endovascular treatment of thoracic aortic lesions involving the aortic arch including chronic dissections, aneurysms, penetrating aortic ulcers and intramural hematoma.

“The TRIOMPHE pivotal study will assess the NEXUSTM in some of the most challenging Aortic Arch Pathologies that we encounter. For the patient, there are limited options to treat these life threatening pathologies. The NEXUSTM device is designed to address most of those complexities through a minimally invasive approach with the potential to provide a safe and durable solution,” indicated the National principal co-investigator, Dr. Ross Milner, Professor of Surgery, Co-Director, Center for Aortic Diseases at the University of Chicago.

Brad Leshnower, Associate Professor of Surgery, Division of Cardiothoracic Surgery, Department of Surgery, Emory University School of Medicine, the National principal co-investigator stated, “There are a significant number of patients who are too high risk for open surgical treatment who are also at significant risk from their aortic arch disease. The NEXUSTM provides an innovative minimally invasive option, which provides cardiac surgeons, if proven safe and effective, the potential to save the lives of patients who would have previously had no other treatment options available.”

Kevin Mayberry CEO of Endospan added, “This is a significant milestone for Endospan in bringing the NEXUSTM towards US patients. We are very encouraged by the European clinical data and commercialization of NEXUSTM in Europe. Starting a pivotal study in the U.S. brings us one step closer to our goal of providing an endovascular approach to treat aortic arch disease pathologies.”

 

SourceEndospan
Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Dr. Sachita Shah, Sr. Director, Global Health, Butterfly Network, "Butterfly is proud to continue improving maternal health equity through Phase Two of the largest-scale handheld ultrasound distribution and training ever conducted in Sub-Saharan Africa. South Africa is an emerging market that continues to have disproportionately high rates of maternal mortality and stillbirth. Patients need easier access to antenatal imaging, and clinicians need better capabilities for screening high-risk conditions that lead to disproportionately worse pregnancy outcomes in rural areas in the public sector. Together with CHAI and GUSI, we can tackle this by making ultrasound much more accessible, so high-risk conditions can be identified earlier in care, which is known to improve outcomes.”
The clinical Study will enroll up to 97 patients at up to 12 European investigational sites. Completion of the study is expected this year, and results will support CE mark and pre-market approval submissions reports Vivasure Medical.
Dr. Michael Newman, Indaptus’ Founder, Chief Scientific Officer, and lead author, commented, “The new data are consistent with our preclinical animal tumor model studies and provide evidence for our hypothesis that patented Decoy bacteria can activate a wide range of innate and adaptive human immune cells involved in fighting tumors.  This aligns with what we’ve observed in our ongoing Phase 1 clinical trial of Decoy20 – broad immune activation, as evidenced by transiently increased levels of many key cytokines and chemokines following single dose administration. These findings bolster our confidence in Decoy20's potential as a multifaceted immunotherapy.”
To further understand the impact of platforms like TikTok on nutrition trends, MyFitnessPal partnered with Dublin City University on a research and experimental study that examined diet and nutrition content on TikTok. The study analyzed over 67,000 videos using Artificial Intelligence to compare them against public health and nutrition guidelines
Leveraging the power of Apple Vision Pro to seamlessly blend digital content with the physical world Osso Health brings the operating experience to life via detailed, clinically accurate workflows of common procedures.

By using this website you agree to accept Medical Device News Magazine Privacy Policy